KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clover Health Investments (CLOV) Liabilities and Shareholders Equity (2019 - 2025)

Clover Health Investments (CLOV) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $541.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 6.84% year-over-year to $541.0 million, compared with a TTM value of $2.3 billion through Dec 2025, up 16.37%, and an annual FY2025 reading of $541.0 million, down 6.84% over the prior year.
  • Liabilities and Shareholders Equity was $541.0 million for Q4 2025 at Clover Health Investments, down from $559.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.7 billion in Q1 2022 and bottomed at $354.7 million in Q4 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $876.9 million, with a median of $634.3 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 133094.34% in 2021, then tumbled 72.48% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $950.8 million in 2021, then tumbled by 62.69% to $354.7 million in 2022, then soared by 60.87% to $570.7 million in 2023, then grew by 1.76% to $580.7 million in 2024, then decreased by 6.84% to $541.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CLOV at $541.0 million in Q4 2025, $559.7 million in Q3 2025, and $575.0 million in Q2 2025.